How to Live to 200 Podcast
Today’s guest is an Emmy-nominated writer and the co-author of Waterman 2.0, The 17 Hour Fast, Game Changer, and Unplugged. Besides being an all around great person, Phil’s work has been a staple of modern athletes and fitness experts. Beginning with Unplugged, he’s helped a new generation re-engage with nature by spending less time indoors and more time outside.
info_outlineHow to Live to 200 Podcast
Our guest today is Dr. Will Cole, a functional medicine expert and the author of the book Ketotarian, a book about the secrets of Vegan and fat adapted dieting. In addition to writing a ground-breaking book, Dr. Cole specializes in investigating underlying factors and creating tailored health programs for chronic conditions such as thyroid issues, autoimmune, hormonal dysfunctions, digestive disorders, diabetes, heart disease and fibromyalgia.
info_outlineHow to Live to 200 Podcast
In this episode, we talk about the API Bob’s built for his personal data, the underlying software architecture, his tracking strategy, and some of the data analysis tools he uses to make sense of the massage amounts of data he’s collecting. If you love to geek-out on apps and tools as much as we do, Bob has you covered. He gives us an inside look at exactly what he uses, how he uses it, and why it’s important.
info_outlineHow to Live to 200 Podcast
In today’s podcast, we learn about Wade’s journey to bodybuilding and the near-encyclopedic knowledge he’s accumulated for enzymes, amino acids, digestion, and physical and mental performance. We really cover a lot of ground in this episode. We spend a while diving into the details of his meditation practice, learning about the machine he uses to customize his water intake, and much more.
info_outlineHow to Live to 200 Podcast
Today’s guest is Ivan Liachko. Ivan is Co-Founder and CEO of a fascinating University of Washington spinout, Phase Genomics. With 20 years of experience and a Ph.D. in Genetics, Ivan is a leading expert in genetic/genomic research. In this episode, we learn all about Lil Bub and how the internet famous cat’s poop helped Ivan discover entirely new organisms. In addition to some incredible discussions about the microbiome, we discuss parabiosis, genomic sequencing, and interesting future-facing technologi
info_outlineHow to Live to 200 Podcast
Our guest today is Stephan Guyenet, Ph.D. Stephan has spent a long time in the neuroscience research world studying neurodegenerative disease and the neuroscience of body fatness. In other words, he knows why it’s so hard to stick to your New Year’s resolution. He’s the author of The Hungry Brain, a book detailing the complex relationship between hormones, habits, and overeating.
info_outlineHow to Live to 200 Podcast
Our guest today is Stephan Guyenet, Ph.D. Stephan has spent a long time in the neuroscience research world studying neurodegenerative disease and the neuroscience of body fatness. In other words, he knows why it’s so hard to stick to your New Year’s resolution. He’s the author of The Hungry Brain, a book detailing the complex relationship between hormones, habits, and overeating.
info_outlineHow to Live to 200 Podcast
Today’s episode is a long overdue discussion on a topic that takes a backseat far too often - women’s health. To help us understand and explore this topic, we enlisted naturopathic doctor and co-director of the Women’s Clinic at Akasha, Dr. Maggie Ney. In our conversation with Dr. Ney, we cover a lot of really interesting topics ranging from recommendations for pregnant women to why she thinks hormone replacement therapy is critical after menopause and the what latest treatments for women’s sexual h
info_outlineHow to Live to 200 Podcast
Our guest today is Matt Kaeberlein, Ph.D., a globally recognized researcher and expert in the biology of aging. Dr. Kaeberlein’s research is based around the premise that understanding the molecular mechanisms of aging will lead to interventions that slow the onset and progression of age-related chronic conditions, such as cancer, diabetes, kidney disease, heart disease, Alzheimer’s and others.
info_outlineHow to Live to 200 Podcast
Our guest today needs no introduction. It is the one and only Aubrey de Grey, a leading biomedical gerontologist, computer scientist, author, and entrepreneur whose work in longevity research is widely known and regularly referenced by many in the industry. He is the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics, Inc. In many respects, Aubrey is one of the most prominent, if not provocative figures in longevity science.
info_outlineLeen Kawas – CEO, M3 Biotechnology
"There's work that needs to be done and we're going to do it." - Leen Kawas
Nothing better illustrates the grit, determination, and enthusiasm of today's guest, Leen Kawas. Leen is the CEO and president of M3 Biotechnology, a Seattle-based startup tackling diseases of the brain. As a leader in her field and an award-winning entrepreneur, she knows no bounds when it comes to tackling the daunting challenge of neurodegenerative diseases like Alzheimer's. As a Ph.D. student at Washington State University, Leen stumbled into an unlikely career as a startup CEO. But Leen's journey to entrepreneurship was completely unplanned.
As an immigrant from Jordan, Leen started her professional journey as a pharmacist. Not long into her career, Leen realized pharmacology didn't suit her ambitions, so she returned to academia, in pursuit of her Ph.D. at Washington State University. The opportunity to move from academia to the startup world came during her time at Washington State University. Like most great entrepreneurs, Leen saw the opportunity and felt compelled to change the status quo. Her passion, intelligence, and charisma quickly catapulted her to the role of CEO. And the rest is, as they say, history.
During our time with Leen, we explore the research behind M3 Biotechnology and find out:
- What happens to our brains as we age?
- What is a cognoscopy?
- What data points can you use to address neurodegeneration?
- What is the difference between small and large molecule treatments?
Leen's charm, wit, and ability to keep T.A. on his toes makes for an incredibly insightful and fun conversation. We hope you enjoy it as much as we did.
Note from Leen: M3 Biotechnology is introducing a new webpage and flyer to support recruitment for our NDX-1017 Phase 1 clinical trials. Please refer to our webpage at ndx-1017.com or call 1-800-839-2095 for more information. Thank you for your interest in our program and novel therapy for Alzheimer’s Disease.